Evotec Investor Presentation Deck

iPSC Platform evotec ¡PSC-based cell types ● PAGE 20 ¡PSC-based cell types gene editing ArrayCGH, karyotyping, WGS ________ ம் IT TOTOO ID www.wand BILD O THE DITE) www UDEILD XX Xx Delivering off-the-shelf cell therapy products to patients EVOcells - seamless R&D continuum integrating discovery, development and manufacturing X INDED F 0 QC & upscaling disease expertise NU NOM XL Pre-clinical development & CMC Single cell sequencing 3D expansion Evotec Clinical manufacturing Partner Clinical development Upscaling ******** Cell QC pluripetency FACE Sede d Cat concentration Markers PCR Germer 5 Marker geres und pee Cleste merhaay an only Calco CC ww OPCH Organ Mebl Marker ge Custer morphology Cel concentration agreed Fre Comtrent FACE 4 Maker poing OPCR Marker ge End stage ty Cluster my ofen Cel concentration • Most advanced programme: E.iBeta - ¡PSC-based islet-like clusters mimicking human islet cells • Partnership with Sernova - iPSC-based beta cell replacement therapy for insulin-dependent Diabetes using Sernova's Cell Pouch™, an implantable medical device for immune protection of E.iBeta Filing of first IND expected in 2024 • Addition of Evotec (Modena) Srl, our Evotec Cell Accelerator, secures reproducible and cGMP-compatible production of E.iBeta batches and represents the broadest and most widely integrated cell therapy platform in the industry Marked supply Marketing and sales cGMP production

View entire presentation